Cargando…

Liver involvement in the drug reaction, eosinophilia, and systemic symptoms syndrome

First described in 1996, the drug reaction, eosinophilia, and systemic symptoms syndrome (DReSS) is considered, along with Stevens-Johnson syndrome and toxic epidermal necrolysis, a severe cutaneous drug reaction. It is characterized by the presence of a maculopapular erythematous skin eruption, fev...

Descripción completa

Detalles Bibliográficos
Autores principales: Martinez-Cabriales, Sylvia A, Shear, Neil H, Gonzalez-Moreno, Emmanuel I
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6448072/
https://www.ncbi.nlm.nih.gov/pubmed/30968035
http://dx.doi.org/10.12998/wjcc.v7.i6.705
_version_ 1783408625152163840
author Martinez-Cabriales, Sylvia A
Shear, Neil H
Gonzalez-Moreno, Emmanuel I
author_facet Martinez-Cabriales, Sylvia A
Shear, Neil H
Gonzalez-Moreno, Emmanuel I
author_sort Martinez-Cabriales, Sylvia A
collection PubMed
description First described in 1996, the drug reaction, eosinophilia, and systemic symptoms syndrome (DReSS) is considered, along with Stevens-Johnson syndrome and toxic epidermal necrolysis, a severe cutaneous drug reaction. It is characterized by the presence of a maculopapular erythematous skin eruption, fever, lymphadenopathy, influenza-like symptoms, eosinophilia, and visceral involvement such as hepatitis, pneumonitis, myocarditis, pericarditis, nephritis, and colitis. The prognosis of patients with DReSS is related to the severity of visceral involvement. The mortality ranges from approximately 5% to 10%, and death is mainly due to liver failure, which is also the organ most commonly involved in this syndrome. Although it was previously hypothesized in 1994, DReSS syndrome can lead to reactivation of one or more human herpesvirus family members. Now being included as diagnostic criteria in a proposed diagnostic score system, this reactivation can be detected up to 2-3 wk after DReSS syndrome onset. Other causes of mortality in DReSS syndrome include myocardial or pulmonary lesions and hemophagocytosis. We reviewed the literature of previously reported case-series of DReSS and liver involvement, highlighting the pattern of liver damage, the treatment used, and the outcome.
format Online
Article
Text
id pubmed-6448072
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-64480722019-04-09 Liver involvement in the drug reaction, eosinophilia, and systemic symptoms syndrome Martinez-Cabriales, Sylvia A Shear, Neil H Gonzalez-Moreno, Emmanuel I World J Clin Cases Minireviews First described in 1996, the drug reaction, eosinophilia, and systemic symptoms syndrome (DReSS) is considered, along with Stevens-Johnson syndrome and toxic epidermal necrolysis, a severe cutaneous drug reaction. It is characterized by the presence of a maculopapular erythematous skin eruption, fever, lymphadenopathy, influenza-like symptoms, eosinophilia, and visceral involvement such as hepatitis, pneumonitis, myocarditis, pericarditis, nephritis, and colitis. The prognosis of patients with DReSS is related to the severity of visceral involvement. The mortality ranges from approximately 5% to 10%, and death is mainly due to liver failure, which is also the organ most commonly involved in this syndrome. Although it was previously hypothesized in 1994, DReSS syndrome can lead to reactivation of one or more human herpesvirus family members. Now being included as diagnostic criteria in a proposed diagnostic score system, this reactivation can be detected up to 2-3 wk after DReSS syndrome onset. Other causes of mortality in DReSS syndrome include myocardial or pulmonary lesions and hemophagocytosis. We reviewed the literature of previously reported case-series of DReSS and liver involvement, highlighting the pattern of liver damage, the treatment used, and the outcome. Baishideng Publishing Group Inc 2019-03-26 2019-03-26 /pmc/articles/PMC6448072/ /pubmed/30968035 http://dx.doi.org/10.12998/wjcc.v7.i6.705 Text en ©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
spellingShingle Minireviews
Martinez-Cabriales, Sylvia A
Shear, Neil H
Gonzalez-Moreno, Emmanuel I
Liver involvement in the drug reaction, eosinophilia, and systemic symptoms syndrome
title Liver involvement in the drug reaction, eosinophilia, and systemic symptoms syndrome
title_full Liver involvement in the drug reaction, eosinophilia, and systemic symptoms syndrome
title_fullStr Liver involvement in the drug reaction, eosinophilia, and systemic symptoms syndrome
title_full_unstemmed Liver involvement in the drug reaction, eosinophilia, and systemic symptoms syndrome
title_short Liver involvement in the drug reaction, eosinophilia, and systemic symptoms syndrome
title_sort liver involvement in the drug reaction, eosinophilia, and systemic symptoms syndrome
topic Minireviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6448072/
https://www.ncbi.nlm.nih.gov/pubmed/30968035
http://dx.doi.org/10.12998/wjcc.v7.i6.705
work_keys_str_mv AT martinezcabrialessylviaa liverinvolvementinthedrugreactioneosinophiliaandsystemicsymptomssyndrome
AT shearneilh liverinvolvementinthedrugreactioneosinophiliaandsystemicsymptomssyndrome
AT gonzalezmorenoemmanueli liverinvolvementinthedrugreactioneosinophiliaandsystemicsymptomssyndrome